FIELD: pharmaceuticals.
SUBSTANCE: invention relates to pharmaceutical industry and biotechnology, namely to means for delivery of an active agent comprising a liposomal suspension complex with a chitosan conjugate which is a compound of formula (C6O4H9NH2)m(C6O4H9NHX)n, wherein the substituent on the amino group X is a monomethoxy-PEG succinate, m and n are the number of units in the molecule, the m/n ratio being 6 to 19, and chitosan is used with a molecular weight of 15,000 to 120,000 Da, while liposomes are associated with the chitosan conjugate non-covalently.
EFFECT: invention provides improvement in stability of liposomal suspensions.
1 cl, 4 dwg
Title | Year | Author | Number |
---|---|---|---|
LIPOSOMAL SUSPENSIONS STABILISER | 2015 |
|
RU2642786C2 |
LIPOSOMAL COMPOSITIONS AND SOLID PERORAL MEDICINAL FORMS COMPRISING SUCH COMPOSITIONS | 2018 |
|
RU2751192C2 |
LIPOSOMAL COMPOSITIONS USED FOR DRUG DELIVERY | 2015 |
|
RU2757110C2 |
LIPOSOMAL COMPOSITIONS APPLICABLE FOR DRUG DELIVERY | 2005 |
|
RU2574926C2 |
TRANSPULMONARY LIPOSOME FOR CONTROLLING DRUG DELIVERY | 2008 |
|
RU2493874C2 |
LIPOSOME SUSPENSION STABILISER AND METHOD FOR PRODUCTION THEREOF | 2013 |
|
RU2529179C1 |
DISPOSABLE SYSTEM FOR STERILE OBTAINING OF LIPIDS AND NUCLEIC ACIDS PARTICLES | 2012 |
|
RU2642640C2 |
IMPROVED LIPOSOMES AND THEIR APPLICATION | 2008 |
|
RU2482837C2 |
TARGETING AMINOACID LIPIDS | 2013 |
|
RU2654210C2 |
LIPOSOMES CONTAINING CELL PENETRATING PEPTIDES AND TETRAESTER LIPIDS FOR ORAL DELIVERY OF MACROMOLECULES | 2016 |
|
RU2743431C2 |
Authors
Dates
2018-10-10—Published
2017-09-08—Filed